Economic evaluations of nonpharmacological treatments for drug‐resistant epilepsy: A systematic review

Abstract

AbstractThis study was undertaken to systematically identify and critically appraise all published full economic evaluations assessing the cost‐effectiveness of nonpharmacological interventions for patients with drug‐resistant epilepsy. The Population, Intervention, Comparison, Outcome, Study criteria was used to design search strategies for the identification and selection of relevant studies. Literature search was performed using the MEDLINE (via PubMed), Embase, International Health Technology Assessment, National Institute for Health Research Economic Evaluation Database, and Cost‐Effectiveness Analysis Registry databases to identify articles published between January 2000 and May 2023. Web of Science was additionally used to perform forward and backward referencing. Title, abstract, and full‐text screening was performed by two independent researchers. The Consensus Health Economic Criteria (CHEC) checklist and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 were applied for quality assessment. A total of 4470 studies were identified, of which 18 met our inclusion criteria. Twelve of the studies conducted model‐based economic evaluation, and others were trial‐based. Three studies showed that epilepsy surgery was cost‐effective in adults, whereas this remained inconclusive for children (two positive, three negative). Three studies showed negative economic outcome for ketogenic diet in children. One of four studies showed positive results for self‐management. For vagus nerve stimulation, one study showed positive results in adults and another one negative results in children. One recent study showed cost‐effectiveness of responsive neurostimulation (RNS) in adults. Finally, one study showed promising but inconclusive results for deep brain stimulation (DBS). The mean scores for risk of bias assessment (based on CHEC) and for reporting quality (CHEERS 2022) were 95.8% and 80.5%, respectively. This review identified studies that assessed the cost‐effectiveness of nonpharmacological treatments in both adults and children with drug‐resistant epilepsy, suggesting that in adults, epilepsy surgery, vagus nerve stimulation, and RNS are cost‐effective, and that DBS and self‐management appear to be promising. In children, the cost‐effectiveness of epilepsy surgery remains inconclusive. Finally, the use of ketogenic diet was shown not to be cost‐effective. However, limited long‐term data were available for newer interventions (i.e., ketogenic diet, DBS, and RNS).